A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors ( PIVOT-02 ) (PIVOT-02)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02983045

Recruitment Status : Active, not recruiting

First Posted : December 6, 2016

Last Update Posted : June 2, 2020

Sponsor:

Collaborator:

Bristol-Myers Squibb

Information provided by (Responsible Party):

Nektar Therapeutics

Study Details
Tabular View
No Results Posted
Disclaimer
How to Read a Study Record

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Estimated Primary Completion Date :	December 2020
Estimated Study Completion Date :	December 2021

To Top